Serum antibodies from MS patients do not recognize HTLV-I, HIV-1, HIV-2 and SIV.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Serum antibodies from MS patients do not recognize HTLV-I, HIV-1, HIV-2 and SIV.

APMIS. 1994 Jul;102(7):514-20. Unique Identifier : AIDSLINE MED/95000583
Brokstad KA; Kalland KH; Page M; Nyland H; Haaheim L; Department of Microbiology and Immunology, Gade Institute,; University of Bergen, Norway.

Abstract: A retroviral aetiology has been proposed for multiple sclerosis (MS). Although there is as yet no definitive evidence of viral involvement, there have been preliminary reports of antiretroviral antibody detection in sera from MS patients. Such sera have, for example, been found to react with HTLV-I. We here describe investigations involving various immunological techniques which attempt to confirm the virus-specific nature of these antibodies against a range of human and macaque retroviruses. Sera from 25 MS patients, 25 patients with non-associated neurological diseases and 16 patients with non-neurological conditions were tested by immunoblotting methods using lysates of HIV-1-, HIV-2-, HTLV-I- and SIV-infected cells as antigens. None of the sera reacted against any of these retroviral antigens but each serum demonstrated a distinctive and reproducible reaction pattern against cellular components of the cells in which the viruses were propagated. Further examination of the sera was carried out by ELISA using synthetic oligopeptides covering the HIV-1 Gag p24 protein as antigens. None of the sera reacted with the peptides. Our results suggest that in some MS patients the repeated seropositivity to HTLV-I may be due to the reaction with host cell proteins.

Keywords: Adult Antibodies/*IMMUNOLOGY Antibodies, Viral/ANALYSIS Antigens, Viral/*IMMUNOLOGY Autoradiography Cross Reactions Enzyme-Linked Immunosorbent Assay Female Human HIV Antigens/*IMMUNOLOGY HIV Core Protein p24/IMMUNOLOGY HIV-1/IMMUNOLOGY HIV-2/IMMUNOLOGY HTLV-I Antigens/*IMMUNOLOGY Immunoblotting Male Middle Age Multiple Sclerosis/*IMMUNOLOGY Support, Non-U.S. Gov't SIV/*IMMUNOLOGY JOURNAL ARTICLE
950130
M9510853

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .